# TNF Pharmaceuticals Inc. (TNFA)

Source: https://www.quantisnow.com/company/TNFA
Generated: 2026-11-19T16:12:50.024Z

- Ticker: TNFA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IPO year: 2014

## Latest TNFA news and filings

- 2025-09-26 21:10 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6213325)
- 2025-09-25 13:15 UTC [Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"](https://www.quantisnow.com/insight/qc-technologies-formerly-tnf-pharmaceuticals-commences-trading-on-nasdaq-under-6211612)
- 2025-09-24 13:15 UTC [TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing](https://www.quantisnow.com/insight/tnf-pharmaceuticals-announces-name-change-to-qc-technologies-and-new-6210247)
- 2025-09-17 13:24 UTC [TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/tnf-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6203597)
- 2025-09-10 21:00 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6196840)
- 2025-09-08 13:15 UTC [Conference Announcement] [TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference](https://www.quantisnow.com/insight/tnf-pharmaceuticals-to-present-at-the-hc-wainwright-27th-annual-6192846)
- 2025-09-05 21:30 UTC [SEC Form 8-K] [Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-tnf-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-6192101)
- 2025-09-05 21:30 UTC [SEC Form D] [SEC Form D filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-tnf-pharmaceuticals-inc-6192100)
- 2025-09-04 13:15 UTC [Public Offering] [TNF Pharmaceuticals Announces Closing of $7 Million Private Placement](https://www.quantisnow.com/insight/tnf-pharmaceuticals-announces-closing-of-7-million-private-placement-6189602)
- 2025-09-02 13:29 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6185342)
- 2025-09-02 13:20 UTC [PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-increases-stake-in-tnf-pharmaceuticals-around-recent-6185323)
- 2025-09-02 13:15 UTC [Public Offering] [TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications](https://www.quantisnow.com/insight/tnf-pharmaceuticals-secures-exclusive-global-rights-to-innovative-light-speed-6185310)
- 2025-08-28 13:15 UTC [TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance](https://www.quantisnow.com/insight/tnf-pharmaceuticals-announces-reverse-stock-split-for-nasdaq-listing-compliance-6181962)
- 2025-08-19 21:20 UTC [TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation](https://www.quantisnow.com/insight/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation-6172217)
- 2025-08-19 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tnf-pharmaceuticals-inc-6172201)
- 2025-08-14 21:01 UTC [SEC Form NT 10-Q filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-tnf-pharmaceuticals-inc-6166969)
- 2025-06-24 13:15 UTC [TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease](https://www.quantisnow.com/insight/tnf-pharmaceuticals-collaborates-with-dada2-foundation-for-compassionate-use-study-6096889)
- 2025-06-06 21:00 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-material-modification-to-6076829)
- 2025-05-19 21:26 UTC [SEC Form DEFR14A filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defr14a-filed-by-tnf-pharmaceuticals-inc-6048598)
- 2025-05-15 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tnf-pharmaceuticals-inc-6042586)
- 2025-05-09 21:30 UTC [SEC Form PRER14A filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-prer14a-filed-by-tnf-pharmaceuticals-inc-6031103)
- 2025-05-09 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-tnf-pharmaceuticals-inc-6031077)
- 2025-05-08 13:20 UTC [TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists](https://www.quantisnow.com/insight/tnf-pharmaceuticals-and-renova-health-report-positive-results-in-identifying-6026433)
- 2025-04-22 13:15 UTC [TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development](https://www.quantisnow.com/insight/tnf-pharmaceuticals-and-renova-health-utilize-ai-to-accelerate-drug-5995951)
- 2025-04-21 21:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-tnf-pharmaceuticals-inc-5995136)
- 2025-04-18 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Vice President, Finance Rauch Gary M](https://www.quantisnow.com/insight/sec-form-4-filed-by-vice-president-finance-rauch-gary-5993697)
- 2025-04-18 20:30 UTC [SEC Form 4] [SEC Form 4 filed by President, CMO Glass Mitchell](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-cmo-glass-mitchell-5993696)
- 2025-04-18 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Interim CFO Rhodes Ian](https://www.quantisnow.com/insight/sec-form-4-filed-by-interim-cfo-rhodes-ian-5993695)
- 2025-04-16 13:15 UTC [TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025](https://www.quantisnow.com/insight/tnf-pharmaceuticals-delivers-platform-presentation-of-oral-tnf-alpha-inhibitor-isomyosamine-5989720)
- 2025-03-31 21:15 UTC [SEC Form NT 10-K filed by TNF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-tnf-pharmaceuticals-inc-5967753)
- 2025-03-21 21:00 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5956300)
- 2025-03-17 13:15 UTC [TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia](https://www.quantisnow.com/insight/tnf-pharmaceuticals-delivers-podium-presentation-of-novel-oral-tnf-alpha-inhibitor-5946661)
- 2025-03-10 21:00 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5936362)
- 2025-03-05 14:00 UTC [Earnings Date] [TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025](https://www.quantisnow.com/insight/tnf-pharmaceuticals-to-host-investor-conference-call-and-webcast-featuring-5927282)
- 2025-02-25 14:20 UTC [TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor](https://www.quantisnow.com/insight/tnf-pharmaceuticals-initiates-phase-2b-clinical-trial-of-first-oral-5907451)
- 2025-01-29 14:15 UTC [TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment](https://www.quantisnow.com/insight/tnf-pharmaceuticals-launches-study-series-aimed-at-preserving-lean-muscle-5861115)
- 2025-01-15 14:15 UTC [TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion](https://www.quantisnow.com/insight/tnf-pharmaceuticals-announces-positive-clinical-data-supporting-clinical-trial-expansion-5846658)
- 2024-12-19 14:15 UTC [TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs](https://www.quantisnow.com/insight/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-5820107)
- 2024-12-09 14:00 UTC [TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference](https://www.quantisnow.com/insight/tnf-pharmaceuticals-presents-statistically-significant-phase-2a-trial-results-for-5805003)
- 2024-11-26 13:05 UTC [SEC Form 8-K] [TNF Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tnf-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-submission-5791348)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TNFA
- Earnings history: https://www.quantisnow.com/earnings/TNFA
- Dividend history: https://www.quantisnow.com/dividends/TNFA
- Insider transactions: https://www.quantisnow.com/insiders/TNFA
- Options chain: https://www.quantisnow.com/options/TNFA
- SEC 8-K filings only: https://www.quantisnow.com/company/TNFA/8-k
- RSS and alerts for TNFA: https://www.quantisnow.com/docs/rss-feeds.md
